Revolution Medicines, Inc. (RVMD) AI Stock Analysis

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing therapies that inhibit targets in RAS-addicted cancers. Headquartered in Redwood City, California, the company's pipeline includes RMC-4630, a SHP2 inhibitor in Phase 1/2 clinical trials for solid tumors such as gynecologic and colorectal cancers. Its development programs also feature RMC-5845 targeting SOS1, RMC-5552 targeting mTORC1 signaling, RMC-6291 targeting KRASG12C(ON) and NRASG12C(ON), and RMC-6236 targeting multiple RAS(ON) variants. In addition, the company maintains a strategic collaboration agreement with Sanofi to research and develop SHP2 inhibitors, including RMC-4630.

Revenue contracted at a 5-year CAGR of -10.5% from FY2018 to FY2023. Annual revenue decreased from $50.0M in FY2019 to $11.6M in FY2023, while net losses expanded from -$47.7M to -$436.4M over the same timeframe. Research and development expenses increased from $91.8M in FY2019 to $423.1M in FY2023. Over the trailing twelve months ended June 30, 2026, revenue stood at $742,000, with quarterly revenue declining 95.2% year-over-year. Diluted earnings per share were -$8.87 over the trailing twelve months, reflecting continued clinical-stage spending without commercial product revenue.

As of June 30, 2026, Revolution Medicines held $3.94B in cash and short-term investments and $641.9M in total debt, resulting in net cash of $3.30B. Total assets stood at $4.32B against shareholders' equity of $2.61B. The company reported a current ratio of 11.38 and a debt-to-equity ratio of 0.25. In FY2025, capital expenditures were $16.0M, while share issuance contributed $8.0M. Its 5-year share count change was 185.6%.

Revolution Medicines trades at a price-to-book ratio of 15.7x, with a market capitalization of $38.14B and an enterprise value of $37.58B. These figures compare to a median price-to-sales ratio of 4.1x, a trailing price-to-earnings ratio of 24.6x, and an enterprise value-to-EBITDA ratio of 12.0x for its US-listed Healthcare peers. The company's stock advanced 258.2% over the past year, exceeding the S&P 500 (SPY) return of 16.8%, and gained 560.3% over the past 5 years versus 83.0% for the index.

Wall Street coverage consists of 18 Strong Buy, 5 Buy, and 1 Hold ratings, with 0 Sell and 0 Strong Sell ratings. The mean price target of $257.80 indicates upside of 44.9% compared to the last close of $177.96 on October 16, 2026. For the current fiscal year ending December 31, 2026, analysts estimate an EPS of -$9.59 and revenue of $188.4M. For next fiscal year, 24 analysts estimate revenue of $1.27B and EPS of -$5.83. The company recorded 0 EPS beats over the last 4 quarters, with its next earnings date scheduled for November 4, 2026.

This page is an AI-written research summary of Revolution Medicines, Inc. (RVMD). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: RVMD income statement, RVMD balance sheet, RVMD key metrics, RVMD analyst forecast, RVMD chart. See the RVMD stock overview for the latest quote and news.